Demographic and clinical characteristics
| Cases, n (%) | 56 (100) |
| Age at 1st visit, mean (SD), years | 35.6 (4.5) |
| BMI, mean (SD) | 23.1 (4.1) |
| Smoke, n (%)neveractiveprevious smoker | 39 (69.7) 6 (10.7) 11 (19.6) |
| Hypertension, n (%) | 3 (5.4) |
| Diabetes, n (%) | 0 (0) |
| Dyslipidemia, n (%) | 1 (1.8) |
| Previous nephritis, n (%) | 9 (16.1) |
| Disease duration, days, median (IQR) | 2845 (998.0–5325.0) |
| ART, n (%) | 13 (23.2) |
| anti-Ro positive, n (%) | 12 (21.4) |
| APL positive, n (%) | 25 (46.3) |
| APS associated, n (%) | 6 (10.7) |
| Never pregnant, n (%) Previous newborn, n (%) Previous abortion, n (%) | 23 (41.1) 33 (59) 23 (41.1) |
| High pregnancy risk, n (%) | 54 (96.4) |
| Preconceptional counselling Pregnant at 1st visit, n (%) Treatment adjustment, n (%) Contraindicated pregnancy, n (%) Not adjustment needed, n (%) | 24 (29.3) 15 (26.8) 2 (3.6) 15 (40.3) |
| Corticosteroid use at 1st visit, n (%) | 15 (26.8) |
| Corticosteroid daily at 1st visit, mg/day, median (IQR) | 5 (2.5–15.0) |
| cDMARDS at 1st visit, n (%) | 11 (19.6) |
| bDMARDs at 1st visit, n (%) | 2 (3.6) |
| Hydroxychloroquine at 1st visit, n (%) | 29 (51.8) |
| Aspirin at 1st visit, n (%) Anticoagulation at 1st visit, n(%) | 16 (28.6) 4 (7.1) |
| Pregnancy, n (%) | 45 (80.4) |
ART (additional reproductive therapies), APL (antiphospholipid antibodies), APS (antiphospholipid syndrome), bDMARDS (biological disease-modifying antirheumatic drugs), BMI (Body Mass Index), RA (rheumatoid arthritis), cDMARDS (conventional disease-modifying antirheumatic drugs).